Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present FibroGen, Inc. (NASDAQ: FGEN).

Full DD Report for FGEN

You must become a subscriber to view this report.


Recent News from (NASDAQ: FGEN)

Notable earnings after Thursday's close
AGO , AL , ALTR , AMBR , AMC , AMPH , AQN , ARRS , ASRT , ATVI , BOJA , BPI , BRS , BW , CBPX , COLD , COLL , CTL , CYRX , DBX , DIS , DOX , ECOM , EGAN , EPAY , ERI , FGEN , FOE , FSCT , FSM , FTCH , GMED , HDP , HTZ , ICUI , JAG , JJSF , LGF.A , LOPE...
Source: SeekingAlpha
Date: November, 07 2018 17:35
FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018
Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT) SAN FRANCISCO, Nov. 02, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that it will report third quarter 2018 financial results on Thursday, November 8, 2018, ...
Source: GlobeNewswire
Date: November, 02 2018 17:02
ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
TOKYO and SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff, “FibroGen”) today announced the presentation of data from two ...
Source: GlobeNewswire
Date: October, 30 2018 04:00
NASH Cirrhosis: The Real NASH Epidemic
Introduction Cirrhosis of the liver threatens the lives of millions of people, and other than a risky, expensive, and temporary transplant, it has no treatment. This marks cirrhosis among those diseases with the greatest unmet medical needs. Healthy liver, left, versus cirrhotic liver...
Source: SeekingAlpha
Date: August, 28 2018 14:19
New Research: Key Drivers of Growth for comScore, Fonar, FibroGen, Resolute Energy, National Commerce, and THL Credit - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of comScore, Inc. (NASDAQ:SCOR), Fonar Corporation (NASDAQ:FONR), FibroGen, ...
Source: GlobeNewswire
Date: August, 15 2018 07:55
FibroGen, Inc. (FGEN) CEO Thomas Neff on Q2 2018 Results - Earnings Call Transcript
FibroGen, Inc. (FGEN) Q2 2018 Earnings Conference Call August 07, 2018, 17:00 ET Executives Karen Bergman - VP, IR & Corporate Communications Thomas Neff - Founder, Chairman & CEO Peony Yu - Chief Medical Officer Christine Chung - VP China Operations Elias Kouchakji -...
Source: SeekingAlpha
Date: August, 07 2018 22:52
FibroGen beats by $0.31, beats on revenue
FibroGen (NASDAQ: FGEN ): Q2 EPS of -$0.28 beats by $0.31 . More news on: FibroGen, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 07 2018 16:05
FibroGen Reports Second Quarter 2018 Financial Results
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic Cancer Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FR...
Source: GlobeNewswire
Date: August, 07 2018 16:02
FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
SAN FRANCISCO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that it will report second quarter 2018 financial results on Tuesday, August 7, 2018, after market close, and will host a conference call to discuss financial results...
Source: GlobeNewswire
Date: August, 01 2018 17:21
Biotech Stocks Are Tariff-Safe And Building Momentum
Biotech Pulse The first half of 2018 saw the Nasdaq Biotechnology Index ( IBB ) make a 52-week high in January and thereafter enter a 5-month consolidation period. Even though the index managed to eke out only a +3% gain in the first half, the second-half has started on a brisk note...
Source: SeekingAlpha
Date: July, 23 2018 10:26

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0857.0056.9557.8056.15305,224
2018-05-1752.2051.3052.4051.15589,481
2017-02-0222.4023.2523.5022.2844500,970
2017-02-0122.7022.6522.8522.30393,182
2017-01-3121.8522.6522.7521.05986,552

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1880,587180,88044.5527Short
2018-12-1774,791132,37456.4998Short
2018-12-1446,453135,10834.3821Cover
2018-12-1354,84375,80872.3446Short
2018-12-1228,47366,17843.0249Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FGEN.


About FibroGen, Inc. (NASDAQ: FGEN)

Logo for FibroGen, Inc. (NASDAQ: FGEN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: FGEN)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 24 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 24 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 01 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 27 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 27 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 23 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 16 2018

       

       


      Daily Technical Chart for (NASDAQ: FGEN)

      Daily Technical Chart for (NASDAQ: FGEN)


      Stay tuned for daily updates and more on (NASDAQ: FGEN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: FGEN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FGEN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of FGEN and does not buy, sell, or trade any shares of FGEN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/